 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE--Regulatory News: NANOBIOTIX Euronext: NANO NASDAQ: NBTX the Company, a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the filing of its universal registration document for the financial year ended December 31, 2020 with the French financial market authority Autorité des marchés financiers or AMF, as well as its annual report on Form 20 